Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × Sunitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Carcinoma, Renal Cell 113 Kidney Neoplasms 36 Neoplasms 31 Neoplasm Metastasis 27 Breast Neoplasms 27 Gastrointestinal Stromal Tumors 26 Carcinoma, Non-Small-Cell Lung 20 Prostatic Neoplasms 12 Urinary Bladder Neoplasms 11 Glioblastoma 11 Colorectal Neoplasms 11 Pancreatic Neoplasms 9 Lung Neoplasms 9 Carcinoma 9 Brain Neoplasms 9 Melanoma 8 Stomach Neoplasms 7 Sarcoma 7 Neuroendocrine Tumors 7 Carcinoma, Hepatocellular 7 Adenoma, Islet Cell 7 Thyroid Neoplasms 6 Small Cell Lung Carcinoma 6 Ovarian Neoplasms 6 Clear-cell metastatic renal cell carcinoma 6 Uveal Melanoma 5 Solid Tumors 5 Multiple Myeloma 5 Liver Neoplasms 5 Leukemia, Myeloid, Acute 5

Interventions

3-Iodobenzylguanidine 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Temozolomide 3 olaparib 2 belzutifan 2 anlotinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Everolimus 2 Biopsy 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 talazoparib 1 spartalizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1 cabozantinib 1 atezolizumab 1 Vorinostat 1 Sunitinib 1 Salts 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01371201 2022-08-04

FIRSTMAPPP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡